Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578

SANOFI (SAN)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Sanofi : Appoints Stefan Oelrich Executive Vice President Diabetes & Cardiovascular and Member of the Executive Committee

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/05/2017 | 10:30am CET

Release date- 04102017 - Paris, France - Sanofi has appointed Stefan Oelrich as Executive Vice President Diabetes & Cardiovascular (DCV), effective immediately.

In this role, Mr. Oelrich will be a member of the Executive Committee.

'Stefan is a highly effective leader who has demonstrated his ability to deliver strong results during his tenure at Sanofi,' said Olivier Brandicourt, Sanofi's Chief Executive Officer. 'As one of the architects of our Diabetes & Cardiovascular business unit, I am confident Stefan will succeed in driving our strategy forward in the coming years.'

Mr. Oelrich has served as head of Sanofi's global diabetes franchise since June 2016 and as acting head of the DCV North America business since July. He will continue to lead both functions ad interim until successors are named.

He previously served as DCV Europe Region Head & Sanofi Europe Coordinator, and was heavily involved in establishing the DCV global business unit since mid-2015. Between 2011 and 2015 he served as General Manager in Germany, Switzerland and Austria.

Mr. Oelrich began his career in Bayer AG in Germany in 1992 where he held positions of increasing responsibility and leadership across Latin America, Europe and the US including General Manager for Bayer Healthcare in Belgium and in France. He led Bayer Pharmaceutical's US Marketing as VP of Marketing followed by a promotion to SVP & General Manager US Women's Healthcare.

A citizen of Germany, Mr. Oelrich holds a Master's degree in Business Administration from the Business School of the Cologne Chamber of Commerce.

About Sanofi

Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi is organized into five global business units: Diabetes and Cardiovascular, General Medicines and Emerging Markets, Sanofi Genzyme, Sanofi Pasteur and Consumer Healthcare. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Contact:

Jack Cox

Tel: +33 (0)1 53 77 46 46

Email: [email protected]

(c) 2017 Electronic News Publishing -, source ENP Newswire

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SANOFI
01/20 SANOFI : refunds gov't with P1.16-B for unused Dengvaxia
01/20 SANOFI : refunds P1.16-B worth of unused Dengvaxia
01/20 SANOFI : Appoints Dominique Carouge Executive Vice President Head of Business Tr..
01/19 SANOFI : Appoints Dominique Carouge Executive Vice President Head of Business Tr..
01/19 SANOFI : Researchers from Sanofi Pasteur Report Findings in Mycoplasma (Validati..
01/19 SANOFI : Researchers from Sanofi Pasteur Describe Findings in Rabies Virus (A no..
01/19 REGENERON PHARMACEUTICALS : and Sanofi To Accelerate and Expand Investment for C..
01/19 NEW DENGUE HEMORRHAGIC FEVER FINDING : Insights From Phase III...
01/18 SANOFI : EDITORIAL - Sober approach
01/18 SANOFI : NBI to submit initial result of probe on Dengvaxia mess
More news
News from SeekingAlpha
01/17 NOVO NORDISK : Don't Spoil The Ablynx Acquisition
01/17 De-Risking Catalysts Aplenty - Cara Therapeutics
01/17 VERTEX PHARMACEUTICALS : Set To Wow In '18
01/16 WALL STREET BREAKFAST : More Records In Store For Equities
01/14 CDC : Worst flu season in years
Financials (€)
Sales 2017 35 761 M
EBIT 2017 9 145 M
Net income 2017 7 967 M
Debt 2017 5 749 M
Yield 2017 4,14%
P/E ratio 2017 11,54
P/E ratio 2018 16,05
EV / Sales 2017 2,74x
EV / Sales 2018 2,69x
Capitalization 92 146 M
Chart SANOFI
Duration : Period :
Sanofi Technical Analysis Chart | SAN | FR0000120578 | 4-Traders
Technical analysis trends SANOFI
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 29
Average target price 83,9 €
Spread / Average Target 15%
EPS Revisions
Managers
NameTitle
Olivier Brandicourt Chief Executive Officer & Director
Serge Weinberg Chairman
Jérôme Contamine Chief Financial Officer & Executive VP-Finance
Elias A. Zerhouni President-Global Research & Development
Yong-Jun Liu Head-Global Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
SANOFI0.72%112 597
JOHNSON & JOHNSON5.20%395 886
NOVARTIS0.61%227 592
PFIZER2.65%220 189
ROCHE HOLDING LTD.-5.40%211 135
MERCK AND COMPANY10.24%167 132